![Tudor G. Jovin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tudor G. Jovin
Direktor/Vorstandsmitglied bei Methinks Software SL
Ursprung des Netzwerks ersten Grades von Tudor G. Jovin
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Methinks Software SL
![]() Methinks Software SL Packaged SoftwareTechnology Services Methinks Software SL provides universal and timely diagnosis to enable life-saving treatments worldwide. The company is based in Barcelona, Spain. The Spanish company's first focus is on stroke, the second cause of death and a major cause of disability in the world. The company was founded by Cristian Martí. Pau Rodríguez has been the CEO of the company since 2019.
4
| Holding Company | Packaged Software | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Tudor G. Jovin
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Roche Glycart AG
![]() Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
Zetta Genomics Ltd.
![]() Zetta Genomics Ltd. Data Processing ServicesTechnology Services Zetta Genomics Ltd. is a British company that focuses on the potential of genomic data to transform research discovery, clinical diagnosis, and the effective application of precision medicine. The company is based in Cambridge, UK, and was founded in 2018. Zetta Genomics is a spin-out from two genomic data pioneers, the University of Cambridge and Genomics England. The company's team is highly talented and diverse, and they explore new and innovative approaches to transforming the future of precision medicine. The company uses a uniquely 'genomic native' technology built on the open-source opencb platform, and their development is led by opencb's chief. The company's goal is to unleash the power of genomic data to improve health outcomes for millions of patients around the world and realize the potential of precision medicine. The CEO is William Spooner. | Data Processing Services | Director/Board Member | |
Instituto de Estudios Superiores de la Empresa | College/University | Masters Business Admin | |
Nina Capital SGEIC SA
![]() Nina Capital SGEIC SA Investment ManagersFinance Nina Capital SGEIC SA (Nina Capital) is a venture capital firm founded in 2019 by Marta Gaia Zanchi. It is headquartered in Barcelona, Spain. | Investment Managers | Director/Board Member | |
Teladoc Health International SA
![]() Teladoc Health International SA Miscellaneous Commercial ServicesCommercial Services Teladoc Health International SA is a medical advisory company. It is engaged in the provision of medical information services and coordination of medical emergencies and medical assistance services at home. The company was founded on May 13, 2004 and is headquartered in Barcelona, Spain. | Miscellaneous Commercial Services | Founder | |
Advance Medical, Inc.
![]() Advance Medical, Inc. Hospital/Nursing ManagementHealth Services Advance Medical, Inc. operates medical hospital and provides home health care services. It offers medical opinions, behavioral care, virtual medical care, pharmaceutical management, and enterprise solutions. The company was founded by Michael Hough in 1999 and is headquartered in Westwood, MA. | Hospital/Nursing Management | Founder | |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Biotechnology | Director/Board Member | |
SpliceBio SL
![]() SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Ona Therapeutics SL
![]() Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Rainier Therapeutics, Inc.
![]() Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member | |
Sanifit Therapeutics SA
![]() Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
Inbiomotion SL
![]() Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Chairman | |
Medlumics SL
![]() Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member | |
TIGENIX NV | Medical Specialties | Director/Board Member | |
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chairman | |
Ysios Capital Partners SGEIC SA
![]() Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Founder | |
Universitat Autònoma de Barcelona | College/University | Undergraduate Degree |
Statistik
International
Spanien | 13 |
Vereinigte Staaten | 4 |
Niederlande | 3 |
Schweiz | 2 |
Vereinigtes Königreich | 2 |
Sektoral
Health Technology | 15 |
Consumer Services | 4 |
Finance | 3 |
Technology Services | 2 |
Commercial Services | 2 |
Operativ
Director/Board Member | 18 |
Founder | 5 |
Chief Executive Officer | 4 |
Chairman | 3 |
Private Equity Investor | 2 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Joël Jean-Mairet | 17 |
Marc Subirats Hofer | 7 |
Cristian Martí | 1 |
Pau Rodríguez | 1 |
- Börse
- Insiders
- Tudor G. Jovin
- Unternehmensverbindungen